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Background: Few epidemiological investigations evaluated the role of smoking cessation on blood pressure (BP),
and the results are not univocal. Therefore, the aim of this study was to assess the effect of smoking cessation on
the risk to develop hypertension (HPT) and on BP values.Methods: This longitudinal study, with a follow-up period
of 8 years, included the participants of the Olivetti Heart Study. Participants were 430 untreated normotensive
non-diabetic men with normal renal function, examined twice in 1994–95 and in 2002–04. The sample included
current smokers (S, n=212), former smokers (ES, n=145) and never smokers (NS, n=73) at baseline. Results: Basal
body mass index (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were significantly higher in
ES than in S (ES vs. S; BMI: 27.0 2.5 vs. 26.1 2.9 kg/m2; P<0.01; SBP/DBP: 121.2 9.3/80.0 5.8 vs. 19.1 9.9/
77.4 6.7mm Hg; P<0.05; M SD). After 8 years of follow-up, BP changes () were significantly lower in ES than
in S (SBP/DBP: 12.6 13.4/7.9 8.1 vs. 16.0 14.9/10.3 10.1mm Hg; P<0.05; M SD), also after adjustment for
potential confounders. Moreover, at the last examination, the overall HPT prevalence was 33%, with lower values
in ES than in S (25 vs. 38%, P=0.01). After accounting for age, BP and BMI at baseline, and changes in smoking
habit over the 8-year period, ES still had significant lower risk of HPT than S (odds ratio 0.30, 95% confidence
interval 0.15–0.58; P<0.01). Conclusions: In this sample of healthy men, smoking cessation was associated with
lower BP increment and minor HPT risk, independently of potential confounders.
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Introduction
The worldwide prevalence of smoking is high, in both Western anddeveloping countries, in men as well as in women.1–3 Strong
evidence supports the association between smoking and risk of car-
diovascular events.4,5
Tobacco smoking is associated with a number of adverse effects
on the cardiovascular system: alterations of the lipidemic profile,6
insulin resistance,7 higher incidence of diabetes8 and metabolic
syndrome.9 Cigarette smoking also increased platelet activation10
and plasma levels of inflammatory markers,11 and it impaired vaso-
dilatation due to decreased nitric oxide synthesis.12 Altogether, these
alterations contribute to the onset and progression of the athero-
sclerotic process.13,14 Moreover, several studies showed that tobacco
smoking leads to endothelial dysfunction,7,14 increases arterial
stiffness15,16 and causes sympathetic system activation.17
The results of cross-sectional investigations on the relationship
between smoking and blood pressure (BP) are not univocal, with
some studies showing a positive18,19 and others an inverse associ-
ation.20 Only few reports describe the possible predictive role of
smoking status on the risk of hypertension (HPT), and their
results suggest an association only in selected subgroup of
subjects.11,21,22 Some observational studies detected an increase in
BP values and HPT prevalence after smoking cessation in men23 and
women.24 Moreover, large epidemiological investigations found a
similar weak risk to develop HPT in former and current smokers
compared with never smokers.11,21 While accounting for waist girth
increments after smoking cessation, who quit smoke was associated
with lower risk of HPT.11 Therefore, the aim of this study was to
assess the effect of cigarette smoking cessation on BP changes and on
the risk to develop HPT in an 8-year follow-up investigation of an




The OHS is an occupational investigation of the male workforce of
the Olivetti factories in Southern Italy (Pozzuoli-Naples and
Marcianise-Caserta). A total of 1085 individuals aged 25–74 years
(51.5 7.2 years) were examined in 1994–95.
At the present examination, we excluded participants who
presented, at baseline, with a diagnosis of HPT [systolic blood
pressure (SBP) 140 mm Hg, diastolic blood pressure (DBP)
90 mm Hg or current antihypertensive therapy] (n= 478), altered
renal function [glomerular filtration rate (GFR) <60 ml/min]
(n= 15) or evidence of diabetes mellitus (fasting blood glucose
level 126 mg/dl or anti-diabetic therapy) (n= 37), as well as
subjects whose demographic and anthropometric characteristics
and cardiometabolic risk factors were not available at baseline
(n= 60). According to these selection criteria, we included 495 in-
dividuals, 430 (87%) of whom had also been examined in 2002–04
and had been considered eligible for the present analysis
(Supplementary Appendix 1). They were stratified into three
groups: smokers (S, n= 212), ex-smokers (ES, n= 145) and never
smokers (NS, n= 73). In particular, ES had mean age of 50.1
years; 67% of participants were overweight, 14% were obese and
10% had central obesity and median of years since quitting was 3
(interquartile range (IQR): 2–4). S aged 49.8 years; 54% were
overweight, 9% were obese and 12% had central obesity. Finally,
NS had mean age of 47.6 years, 55% were overweight, 10% were
obese and 8% had central obesity (table 1).










The local Ethics Committee approved the study protocol, and the
participants provided their informed consent to participate.
Study protocol
The OHS study procedures have been previously described.25 The
examination at the baseline and at the end of the study was
performed between 08:00 and 11:00 h, in a quiet and comfortable
room, with the participants having fasted for at least 13 h. The par-
ticipants had been instructed to pursue their normal activities but to
avoid vigorous exercise and abstain from smoking and drinking
alcohol, coffee, tea or any other beverages containing caffeine
starting the evening before the visit.
The visit included a physical examination, the measurements of
anthropometric parameters, a blood test, a fasting timed urine
collection and the administration of a questionnaire including in-
formation on medical history, physical activity at work and during
leisure time and alcohol consumption.
A fasting venous blood sample was obtained for the determination
of serum glucose, insulin, creatinine, high-sensitive C-reactive
protein (CRP) and lipids. Blood specimens were immediately
centrifuged and stored at 70C until analysis. Serum total choles-
terol, triglyceride, glucose and CRP levels were measured with
automated methods (Cobas-Mira; Roche, Milan, Italy). Serum
insulin concentrations were measured by radioimmunoassay
(Insulina Lisophase; Technogenetics, Milan, Italy). Insulin sensitivity
was estimated by the homeostasis model assessment (HOMA) using
the following formula: fasting plasma insulin (U/ml) fasting
plasma glucose (mmol/l)/22.5.
GFR (expressed as ml/min) was assessed by the following formula:
[140 age (years)weight (kg)]/[72 serum creatinine (mg/dl)].
Baseline smoking status was investigated by a previously validated
questionnaire comprising 11 questions.26 The questionnaire
classified the participants into current smokers, never smokers and
ex-smokers, and reported the number of cigarettes per day, the
duration of smoking habits and the number of years since cessation.
SBP and DBP (phase V) were measured three times, 2 min apart,
with a random zero sphygmomanometer (Gelman Hawksley Ltd.,
Sussex, UK) after the subject had been sitting for at least 10 min. The
average of the second and third reading was recorded.
The diagnosis of incident HPT during the 8-year follow-up period
was defined as SBP 140 and/or DBP 90 mm Hg or current use of
antihypertensive drug treatment (according to European Society of
Hypertension/European Society of Cardiology guidelines).27
Moreover, we also adopted more stringent criteria to detect HPT
occurrence at follow-up (i.e. SBP 160 and/or DBP 95 mm Hg or
current antihypertensive treatment at follow-up). These criteria were
adopted to avoid the HPT prevalence overestimation, which would
be possible because BP was measured only one time in the clinical
visit.
Physical activity level was expressed according to whether the
participant habitually engaged at least 30 min/day of aerobic
exercise (YES/NO). Participants were also classified according to
their alcohol intake into two groups: at least one glass of wine
(or an equivalent amount of other alcoholic beverages per day)
(YES) or no alcohol consumption (NO).
Hypercholesterolaemia was defined as a fasting blood total chol-
esterol level 190 mg/dl or use of lipid-lowering medication (YES),
and hypertriglyceridaemia as fasting blood triglyceride levels
150 mg/dl or use of lipid-lowering medication (YES).27
Body weight, height and abdominal circumference were measured
as described.25 Overweight was defined as a body mass index (BMI)
25 kg/m2 and obesity as a BMI 30 kg/m2. Central obesity was
given by a abdominal circumference value 102 cm.27
Statistical analysis
Statistical analyses were performed using the SPSS software, version
15 (SPSS Inc., Chicago, IL). As the distributions of HOMA index,
GFR and CRP (based on 340 participants) were skewed
(Kolmogorov–Smirnov test: P< 0.01), we based our analyses on
the log-transformed values of HOMA index (Kolmogorov–
Smirnov test: P= 0.28), GFR (Kolmogorov–Smirnov test: P= 0.23)
and CRP (Kolmogorov–Smirnov test: P= 0.94).
To assess differences between group means, analysis of variance
was used, followed by the Bonferroni correction for multiple com-
parisons, whereas chi-squared test was used to evaluate differences
Table 1 Baseline characteristics of study participants
Variable Total Ex-smokers Smokers Never smokers
N 430 145 212 73
Age (years) 49.56.6 50.15.4**** 49.86.6 47.6 8.3***
BMI (Kg/m2) 26.42.8 27.02.5**,**** 26.12.9 26.0 2.9
Overweight (%) 58 67** 54 55
Obesity (%) 11 14** 9 10
SBP (mm Hg) 119.89.9 121.29.3* 119.19.9 118.9 10.9
DBP (mm Hg) 78.56.5 80.05.8** 77.46.7 78.7 6.7
Heart Rate (b/min) 60.27.6 61.67.9** 59.27.5 60.4 7.0
Optimal BP (%) 34 29 37 33
Normal BP (%) 52 53 51 52
High-Normal BP (%) 14 18 12 15
Abdominal circumference (cm) 92.78.0 94.16.1*,**** 92.48.4 91.0 9.8
Central obesity (%) 11 10 12 8
GFR (ml/min)a 87.11.2 91.21.2 88.01.2 91.2 1.0
HOMA index (U)a 1.71.6 1.81.7 1.71.6 1.8 1.6
CRP (mg/l)a,b 1.12.5 0.92.3** 1.32.4 0.9 3.0***
Hypercholesterolaemia (%) 81 82 80 79
Hypertriglyceridaemia (%) 41 39 46 30***
Physical activity (%) 32 35 32 27
Alcohol use (%) 81 85**** 83 68***
Data are expressed as means SD, or as percentages; CRP: high-sensitive C-reactive protein; SBP, systolic blood pressure;
DBP, diastolic blood pressure.
a: Geometric mean.
b: Analysis based on 340 participants.
Ex-smokers vs. smokers: *P<0.05, **P<0.01. Never smokers vs. smokers: ***P<0.05.
Ex-smokers vs. never smokers: ****P<0.05.










between categorical variables. Bivariate relationships between the
variables under investigation were evaluated by Pearson correlation
analysis. Multiple linear regression analysis was used to determine
the independent effect of smoking on BP levels, adjusting for
baseline age, BMI, BP, heart rate and antihypertensive therapy and
cigarette smoking at follow-up, and additional model, based on 340
subjects, was also accounted for CRP. Binary logistic regression
analysis was used to estimate the role of cigarette smoking on
incidence of HPT, adjusting for baseline age, BMI or changes in
BMI, SBP and heart rate, and cigarette smoking at follow-up.
Further model based on 340 participants was adjusted also for CRP.
It was estimated that 134 subjects were required in each arm to
detect a true difference of 3.4 mm Hg in SBP changes over time, and
to provide 80% power at 5% probability level (two-sided).
The results are reported as mean or geometric mean SD or SE or
as percentages or as odds ratio (OR) and 95% confidence interval
(CI), unless otherwise indicated. Two-sided P< 0.05 was considered
statistically significant.
Results
In the whole population sample of the OHS in the 1994–95 exam-
ination, the current smokers were 43%, ex-smokers 37% and never
smokers 20%. This distribution was slightly higher than that
reported by official Italian registries, matching for gender, age and
year28,29 (figure 1).
Baseline relevant characteristics of the sample are reported in
table 1. The prevalence of overweight was 58%, obesity 11% and
central obesity 11%. Mean duration of smoking habit was 29 years
[median: 30 years, (IQR: 25–35)] and mean number of cigarettes per
day 18 [median: 20, (IQR: 10–25)]. During the study, 20% (n= 42)
of S quit smoking and nobody started smoking. The comparison, at
baseline, between ES and S showed that BMI, SBP, DBP, heart rate
and abdominal circumference were significantly higher in ES than in
S (ES vs. S; BMI: 27.0 2.5 vs. 26.1 2.9 kg/m2, P< 0.01; SBP:
121.2 9.3 vs. 119.1 9.9 mm Hg, P< 0.05; DBP: 80.0 5.8
vs. 77.4 6.7 mm Hg, P< 0.01; heart rate: 61.6 7.9 vs.
59.2 7.5 b/min, P< 0.05; abdominal circumference 94.1 6.1 vs.
92.4 8.4 cm, P< 0.05). Besides, CRP was significantly lower in ES
(ES vs. S: 0.9 2.3 vs. 1.3 2.4 mg/l, P< 0.01) (table 1).
Otherwise the comparison between ES and NS indicated a signifi-
cantly lower age, BMI, abdominal circumference and alcohol con-
sumption in NS (NS vs. ES: age, 47.6 8.3 vs. 50.1 5.4, P< 0.05;
BMI: 26.0 2.9 vs. 27.0 2.5 kg/m2, P< 0.05; abdominal circumfer-
ence: 91.0 9.8 vs. 94.1 6.1 cm, P< 0.05; alcohol use: 68 vs. 85%,
P< 0.05).
Finally, the comparison between NS and S subjects showed that
NS were younger, consumed less alcohol and had lower CRP and
hypertriglyceridaemia than S (NS vs. S: age 47.6 8.3 vs. 49.8 6.6,
P< 0.05; alcohol use: 68 vs. 83%, P< 0.05; CRP: 0.9 3.0 vs.
1.3 2.4 mg/l, P< 0.05; hypertriglyceridaemia: 30 vs. 46%, P< 0.05).
After the 8-year follow-up, the changes () in BP were signifi-
cantly lower in ES than in S (ES vs. S; SBP: 12.6 13.4 vs.
16.0 14.9 mm Hg, P= 0.03; DBP: 7.9 8.1 vs. 10.3 10.1 mm
Hg, P= 0.02); in addition, in a full multivariate model, after ac-
counting for all potential confounders, SBP changes remained sig-
nificantly lower in the ES group. On the contrary, DBP changes did
not reach statistical significance (table 2). In addition, also BMI,
abdominal circumference, HOMA index, GFR and CRP were not
significantly different between ES and S during the follow-up.
The comparison between ES vs. NS showed that both groups had
similar BP values (ES vs. NS: SBP 12.6 13.4 vs. 11.9 11.6 mm
Hg - DBP: 7.9 8.1 vs. 8.5 8.5).
According to European Society of Hypertension/European Society
of Cardiology guidelines, the incidence of HPT after 8 years of
follow-up was 54%, whereas according to the more stringent
criteria of HPT, incidence was 33%, and was significantly different
only between ES and S (ES = 25%, S = 38%, P= 0.01). This difference
was confirmed by a logistic regression analysis, also accounting for
baseline age, BMI, SBP, heart rate and smoking habit at follow-up
(ES vs. S, OR 0.30, 95% CI 0.15–0.58, P< 0.01). In addition,
adjusting for CRP, HPT risk remained significantly lower in ES
subjects (OR 0.28, 95% CI 0.14–0.57, P< 0.01). The predictive role
of cigarette smoking remained statistically significant also in a model
including BMI changes throughout the study (table 3).
Finally, the analysis of the possible relationship between duration
of smoking habit, number of cigarette smoked per day or duration
of smoking cessation and changes in BP during the observational
period did not show significant associations.
Discussion
For the first time, an epidemiological study shows that in people who
quit smoking, BP and risk of HPT over time are similar to those of
never smokers and significantly lower than those of current smokers.
These results are not affected by duration of smoking cessation.
Two large prospective studies have investigated the relationship
between cigarette smoking and risk of HPT. One of them involved
Table 2 Eight-year changes in blood pressure in ex-smokers
compared with smokers
Model Changes in SBP P-value
SE
Unadjusted 3.40 1.54 0.028
Multivariate Model 1a 5.49 2.02 0.007
Multivariate Model 1 bisb 5.66 2.04 0.006
Model Changes in DBP P-value
 SE
Unadjusted 2.371.01 0.019
Multivariate Model 2c 1.461.32 0.267
Multivariate Model 2 bisd 1.621.33 0.222
SBP, systolic blood pressure; DBP, diastolic blood pressure.
a: Adjusted for baseline age, BMI, SBP (rank), heart rate and
antihypertensive therapy and cigarette smoking at follow-up.
b: Model 1 plus baseline CRP (high-sensitive C-reactive protein):
based on 340 participants).
c: Adjusted for baseline age, BMI, DBP (rank), heart rate and
antihypertensive therapy and cigarette smoking at follow-up.
d: Model 2 plus baseline CRP (high-sensitive C-reactive protein):
based on 340 participants.
Figure 1 Prevalence of smokers in the Olivetti Heart Study (OHS) at
baseline (1994–95) and in Italian general male population in 1994–
95 (data from Italian registries28,29). *Data of Italian general male
population matched for age (data available only for smokers)










13 000 male participants and found that compared with never
smokers, past smokers and current smokers had similar risk of
HPT.11 The other study included 28 000 female participants, and it
found a weak, but greater, risk of HPT in former smokers than in
never smokers.21 However, these two investigations were based on
self-reported BP and anthropometric values, and furthermore, did
not adjust for changes in weight during the follow-up, nor did they
provide information on smoking cessation. Conversely, our results
are based on direct measurement of BP values in both examinations
and take into account the changes in body weight during follow-up
as covariate in the multivariate model.
Two other prospective studies focalized the investigation on
smoking cessation, and found that it was positively associated with
both risk of HPT and changes in BP during weight variations.23,24
Janzon et al examined only current smokers, who were divided on
the basis of their changes in smoking habits during follow-up. This
study showed that the women who quit smoking had higher weight
gain with greater BP increase and risk of HPT than never smokers or
current smokers.24 On the contrary, our results showed that weight
increases during follow-up were similar between ex-smokers, current
smokers and never smokers; furthermore, although we adjusted for
changes in smoking habit during follow-up, ex-smokers were con-
sidered those who were former smokers at baseline.
In a study evaluating only male individuals, the participants who
quit smoking had higher risk of HPT and BP increase than current
smokers and non-smokers, also after stratification by weight
changes.23 In addition, Lee et al indicated a similar risk of HPT
between current smokers and non-smokers. These results were
based on single BP determination during the 4 years of follow-up,
and the authors considered as ex-smokers those who quit smoking
during the follow-up. Our investigation, which was based on an
8-year follow-up, considered the average of three BP measurements,
both at baseline and at follow-up, and included as ex-smokers the
subjects who had quit smoking before the baseline examination, and
in the multivariate model, we also adjusted for changes in smoking
habit during follow-up.
Finally, a longitudinal investigation of a relatively small cohort of
middle-aged men reported an inverse association between smoking
cessation and the risk of HPT, although this association achieved
statistical significance only after adjustment for basal waist girth and/
or changes in waist girth during follow-up.11 On the contrary, our
study found this inverse association not only after adjustment for
covariates, but also in the linear model.
In conclusion, our study is the first prospective investigation of
the relationship between cigarette smoking and risk of HPT based on
direct measurement of BP, anthropometric indexes and related bio-
chemical variables at both baseline and follow-up examinations. To
the best of our knowledge, this is the first investigation to demon-
strate a significant association between smoking cessation at baseline
and subsequent rate of HPT and BP decline, independently of age,
BP, BMI, physical activity, alcohol intake, kidney function, insulin
resistance, heart rate and CRP at baseline, and of intercurrent
changes in body weight and smoking habits.
An ancillary finding of our study was that DBP at baseline was
significantly higher in ES than in S, as also reported in other epi-
demiological studies20,30 and in a case–control study on hypertensive
individuals.31 In our opinion, this significant difference could be
traced to the direct association between DBP and BMI, which, in
turn, was higher in the ES than in the S group.
The second important result of our study is the association
between cigarette smoking cessation and BP changes during the 8-
year follow-up. This result is in agreement with previous studies
reporting that smoking could affect central hemodynamic
parameters and arterial stiffness.15,32 It is important to note that
our investigation found similar changes in BP and risk to develop
HPT in the ES and NS groups. This result confirms previous inves-
tigations showing a significant reduction of cardiovascular risk in
former smokers compared with current smokers after 1 year of
smoking cessation.33
With regard to the duration of smoking cessation, the analysis did
not show association with BP over time. These results were
supported by the homogeneity of duration of smoking cessation
in the sample participants (and by the stability of the changes in
BP and in body weight over the years).
Our study has some limitations. Firstly, it addressed white adult
male individuals only, hence its results can only be generalized to a
white adult male population. Secondly, as intermediate BP measure-
ments from baseline to end of observation were not available, time-
to-event analyses on incidence of HPT are not feasible.
The strengths of this investigation are the prospective design of
the study with a relatively long follow-up observation period, direct
measurement of BP and related variables at both baseline and
follow-up, stringent criteria for diagnosis of incident HPT, careful
standardization of data collection and inclusion of an unselected
population sample.
The results of our study showed a favourable association between
smoking cessation and BP decrease over time and risk to develop
HPT in an adult sample of generally healthy men.
These results support the recommendations to abstain from
smoking or stop smoking to reduce cardiovascular risk and, in
particular, to prevent HPT development and increase BP levels
with age.
Supplementary Data
Supplementary data are available at EURPUB online.
Conflict of interest: None declared.
Key points
 This investigation shows that smoking cessation protects
from HPT risk.
 This article underlines for the first time that smoking
cessation prevents from BP increments in general male
population, independently of changes in body weight.
 These results support the recommendations to abstain from
or to stop smoking to reduce cardiovascular risk. In
addition, they underline the necessity of smoking cessation
to prevent the development or the worsening of the cardio-
vascular risk determined by HPT.
Table 3 Eight-year risk of incident hypertension in ex-Smokers
compared with smokers
Model Risk of incident hypertension P-value
OR (95% CI)
Unadjusted 0.55 (0.35–0.88) 0.013
Multivariate Model 1a 0.30 (0.15–0.58) 0.001
Multivariate Model 1 bisb 0.28 (0.14–0.57) 0.001
Multivariate Model 2c 0.38 (0.19–0.76) 0.006
Multivariate Model 2 bisd 0.37 (0.18–0.74) 0.005
OR, odds ratio of ex-smokers vs. smokers; SBP, systolic blood
pressure.
a: Adjusted for baseline age, BMI, SBP and heart rate, and cigarette
smoking at follow-up.
b: Model 1 plus baseline CRP (high-sensitive C-reactive protein):
based on 340 participants.
c: Adjusted for baseline age, SBP and heart rate, BMI changes and
cigarette smoking at follow-up.
d: Model 2 plus baseline CRP (high-sensitive C-reactive protein):
based on 340 participants.
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